Nachrichten zur Bristol-Myers Squibb Co Aktie

Bristol-Myers Announces Sale of Celgenes Otezla to Amgen

Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process....…

Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO Technology

SEATTLE , Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences, a cancer biotechnology company pioneering a…

Amgen to buy Celgene’s psoriasis drug Otezla for £10.9bn

Otezla is being divested in connection with the ongoing regulatory approval process for the pending merger between Bristol-Myers Squibb and…

What Happened in the Stock Market Today

Bristol-Myers Squibb and Celgene made a deal to sell a blockbuster drug to Amgen, and Disney and Target are forming…

Jim Cramer: Heres How Amgens Otezla Deal Impacts Bristol-Myers-Celgene Merger

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

Amgen Inc will buy Celgene Corps psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb…

Amgen to spend $13.4B on Celgene psoriasis drug Otezla

Celgene will unload the psoriasis treatment Otezla for $13.4 billion to help make its acquisition by fellow drugmaker Bristol-Myers pass…

Bristol-Myers verkauft Blockbuster-Medikament für Celgene-Übernahme

Um den gesamten Artikel unter de.reuters.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mega-Deal: Amgen kauft zu - Fusion zwischen Celgene und Bristol-Myers Squibb rückt näher

Amgen erwirbt das Schuppenflechte-Medikament Otezla von Celgene für 13,4 Milliarden Dollar in bar. Damit kommen Celgene und Bristol-Myers Squibb der…

Bristol-Myers verkauft Blockbuster-Medikament für Celgene-Übernahme

Frankfurt (Reuters) - Der US-Pharmakonzern Bristol-Myers Squibb ebnet sich den Weg für die 74 Milliarden Dollar schwere Übernahme des Biotechunternehmens…

Pharmaindustrie: Bristol-Myers verkauft Blockbuster-Medikament für Celgene-Übernahme

Das Pharmazieunternehmen hofft auf die Zustimmung der Kartellbehörde für die geplante Übernahme von Celgene. Es wäre die größte Übernahme der…

Celgene to sell psoriasis drug Otezla for $13.4 billion to Amgen

Celgene Corp will sell its psoriasis drug Otezla for $13.4 billion in cash to Amgen Inc, taking Celgene a step…

Amgen to Buy Otezla for $13.4 Billion in Cash

Amgen said Monday it had agreed to buy the psoriasis treatment Otezla from Celgene for $13.4 billion in cash in…

Amgen to buy Celgenes Otezla for $13.4 billion

Shares of Amgen Inc. fell 1.0% in premarket trading Monday after the biotechnology company said it agreed to buy…

Amgen to buy Celgenes psoriasis drug Otezla for $13.4 billion in cash

Amgen Inc said on Monday it would buy Celgene Corps psoriasis drug Otezla for $13.4 billion in cash,…

Can Eliquis Continue To Add $1 Billion In Annual Sales For Bristol-Myers Squibb-

Bristol-Myers Squibbs (NYSE:BMY) Eliquis is a leading novel oral anticoagulant, which refers to blood thinners that treats, prevents, and reduces…

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon...…

Top Stock Reports for Home Depot, Abbott & Bristol-Myers

Top Stock Reports for Home Depot, Abbott & Bristol-Myers...…

The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes

The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes...…

The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer

The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer...…

What Has Led Bristol-Myers Squibbs Stock To Fall More Than 35% Over The Last 3 Years-

Bristol-Myers Squibbs (NYSE:BMY) stock price has fallen by over 35% over the last three years, despite a growth in revenues,…

Thinking about trading options or stock in AbbVie, Bristol-Myers Squibb, Goldman Sachs, Johnson & Johnson, or Micron Technology-

NEW YORK , Aug. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for…

Top Research Reports: Bristol-Myers, CME Group, Chubb & More

Top Research Reports: Bristol-Myers, CME Group, Chubb & More...…

Celgene: Timing The Switch To Bristol-Myers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Notable Insider Buys: AbbVie, Bristol-Myers And More

Insider buying can be an encouraging signal for potential investors. Insiders were buying shares last week in the wake of earnings…

Bristol-Myers Looks Incredibly Cheap

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now-

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from…

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid…

Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Bristol-Myers Squibb Co (BMY) Q2 2019 Earnings Call Transcript

BMY earnings call for the period ending June 30, 2019....…

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

5 Things You Need to Know From Bristol-Myers Squibbs Q2 Earnings Update

The big pharma company had good news and bad news. But the good news outweighed the bad....…

UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on…

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter…

Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View

Bristol-Myers (BMY) beats both earnings and sales estimates in the second quarter, primarily on robust sales of Opdivo and Eliquis.…

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

Bristol-Myers Squibb , which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected…

UPDATE 1-Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on…

Bristol-Myers earnings beat fails to lift stock

Bristol-Myers Squibb Co. topped earnings expectations in the second quarter, but disappointing cancer trial results seemed to weigh on shares…

Drug-Trial Data Hurts Bristol Myers, but Earnings Could Triumph

Shares of Bristol-Myers Squibb were down in premarket trading on Thursday, despite an earnings report that beat Wall Street expectations....…

US-Pharmakonzern Bristol-Myers Squibb wächst und schraubt Prognose hoch

NEW YORK (dpa-AFX) - Der Pharmakonzern Bristol-Myers Squibb (BMS) (Bristol-Myers Squibb) hat dank eines guten Arzneimittelgeschäfts im zweiten Quartal deutlich…

US-Pharmakonzern Bristol-Myers Squibb wächst und schraubt Prognose hoch

NEW YORK (dpa-AFX) - Der Pharmakonzern Bristol-Myers Squibb (BMS) hat dank eines guten Arzneimittelgeschäfts im…

Bristol-Myers tops revenue and profit expectations, but lowers full-year earnings guidance

Bristol-Myers Squibb Co. reported second-quarter earnings Thursday that topped profit and revenue expectations. Profit for the latest quarter rose…

The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lillys Nasal Low Blood Sugar Drug

Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week…

Bristol-Myers Tops Q2 Profit Forecast, Boosts 2019 Guidance, as Elquis Impresses

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Shares of drugmaker Bristol-Myers fall after another setback for its biggest-selling cancer drug

Um den gesamten Artikel unter bloom.bg zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb Falls After Results of Cancer Treatment Study Disappoint

Bristol-Myers Squibb stock fell in after-hours trading on the back of disappointing data for a combination cancer treatment with its…

Bristol-Myers releases mixed Opdivo lung cancer results

Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy…

Bristol-Myers Squibb stock falls on lung cancer drug study result

Bristol-Myers Squibb Co. fell in the extended session Wednesday after the drug maker said its lung cancer drug did…

Buy Celgene, Sell Bristol-Myers Squibb Ahead Of Merger Closing

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…